Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery
Posted on: Monday, 27 April 2009, 07:00 CDT
"Cellectricon's unique high throughput microfluidic screening platform
allows us to further develop our leading platform for ion channel screening.
This collaboration gives us the opportunity to increase the throughput we
provide for customers as well as the number of ion channel subtypes we can
screen in an electrophysiology-based format," said Dr.
"Cellectricon is very pleased to provide BioFocus DPI with this
state-of-the-art enabling technology that enhances their ion channel drug
discovery offering," said
About Dynaflow(R)HT System
The Dynaflow(R)HT microfluidic ion channel screening platform is the world's first APC technology enabling high throughput screening of all kinds of ion channels - voltage gated or ligand gated. Fully automated, the Dynaflow(R)HT has a throughput exceeding all existing APC systems - at a very competitive running cost. Rapid compound exchange enables highly complex perfusion protocols, gives superior data quality, and reduces compound usage. The new Dynaflow(R)HT screening platform is developed in close collaboration with leaders in the pharmaceutical industry.
About Cellectricon
Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007, the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.
http://www.cellectricon.com Contact details Jonas Ohlsson, CEO, Phone: +46(0)709-73-47-92, E-mail: jonas.ohlsson@cellectricon.com. Susanne Fagerlund, VP Marketing & Communications, Phone: +46(0)31-760-35-15, E-mail: susanne.fagerlund@cellectricon.com.SOURCE Cellectricon AB
Source: PR Newswire
Related Articles
- Researchers Take Look At Ion Channels In A Model System
- Reportlinker Adds Ion Channel Modulator Pipelines: Targets and Agents in Development
- ChanTest to Highlight Expanded Ion Channel and GPCR Services and Cell Lines, Including FDA Critical Path Safety Profiling Tools at ToxExpo, Booth 3056
- Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
- Icagen Provides Update for Clinical Development of Senicapoc, a Novel Oral Small Molecule Ion Channel Blocker
- Sigma Launches The New Ion Channel Solutions Brochure and Web Site
- Sugar in Ion Channel Proteins Studied
- CORRECTING AND REPLACING Clear Channel Radio Announces Rating-System RFP Finalists, Evaluation Team
- TranSwitch Corporation Introduces TEPro-Fx28 for Channelized T1/E1 Access Systems
 |
 |
User Comments (0)
RSS Feeds